ClinConnect ClinConnect Logo
Search / Trial NCT05696769

Tourette Discrimination (TD) Stigma Scale

Launched by WAKE FOREST UNIVERSITY HEALTH SCIENCES · Jan 12, 2023

Trial Information

Current as of June 26, 2025

Recruiting

Keywords

Stigma

ClinConnect Summary

This clinical trial, called the Tourette Discrimination (TD) Stigma Scale, is exploring the challenges faced by children and young adults with Chronic Tic Disorders (CTD), which includes Tourette Syndrome. The main goal is to understand how stigma and discrimination affect their lives. By gathering this information, the researchers hope to find better ways to support individuals with CTD in the future.

The study is currently looking for participants aged 8 to 30 who have been diagnosed with CTD by a doctor. If you are a parent, caregiver, or supporter of someone with CTD and you've been involved in their care, you can also take part. However, participants need to speak English and should not have certain conditions, like intellectual disabilities or psychosis, that might make it hard for them to understand the study. If you join the study, you can expect to share your experiences and insights, which will be valuable for understanding and addressing the stigma surrounding tic disorders.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • CTD Cohort
  • 1. Physician-confirmed diagnosis of CTD based on the Diagnostic and Statistical Manual for Mental Disorders-Fifth Edition (DSM-V) criteria
  • 2. 8-30 years old.
  • Parent/caregivers, supporters, medical providers, advocate cohort (s)
  • 1. Involved in the care of a child, youth or young adult with CTD
  • 2. The known person with CTD has had tics for more than a year at the time of screening
  • Exclusion Criteria:
  • CTD Cohort
  • Exclusion criteria:
  • 1. Non-English speaking
  • 2. Diagnosis of intellectual disability
  • 3. Diagnosis of psychosis
  • 4. Any other condition that, in the Principle Investigator's opinion, would limit the participant's (or parent's) ability to understand study measures.
  • Parent/caregivers, supporters, medical providers, advocate cohort (s)
  • 1) The known person with CTD has an intellectual disability or diagnosis of psychosis

About Wake Forest University Health Sciences

Wake Forest University Health Sciences is a leading academic research institution dedicated to advancing healthcare through innovative clinical trials and translational research. With a strong emphasis on multidisciplinary collaboration, the organization leverages its extensive expertise in medical research, patient care, and education to develop and evaluate new therapies and interventions. Committed to improving patient outcomes and public health, Wake Forest University Health Sciences fosters a dynamic environment for scientific inquiry, engaging in a wide range of clinical studies that address pressing health challenges. Through its rigorous methodologies and ethical standards, the institution aims to contribute significantly to the medical field and enhance the quality of life for diverse populations.

Locations

Winston Salem, North Carolina, United States

Patients applied

0 patients applied

Trial Officials

Jaclyn M Martindale, DO

Principal Investigator

Wake Forest University Health Sciences

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials